NurOwn of ‘Meaningful’ Benefit to Earlier Stage Patients, Data Show

NurOwn of ‘Meaningful’ Benefit to Earlier Stage Patients, Data Show

313217

NurOwn of ‘Meaningful’ Benefit to Earlier Stage Patients, Data Show

Brainstorm Cell Therapeutics‘ investigational cell-based therapy, NurOwn, might be able to slow disease progression and be of “meaningful” benefit to  people with less severe amyotrophic lateral sclerosis (ALS), according to new analyses of Phase 3 trial data. The company announced last year that its Phase 3 trial (NCT03280056) had failed to meet its primary goal of slowing disease progression in treated patients relative to those given a placebo. The U.S. Food and Drug Administration, after…

You must be logged in to read/download the full post.